^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TLR9 expression

i
Other names: Toll Like Receptor 9, Toll-Like Receptor 9, CD289, CD289 Antigen, TLR9
Entrez ID:
1m
Bovine papillomavirus gene expression and inflammatory pathway activation vary between equine sarcoid tumour subtypes. (PubMed, Vet Immunol Immunopathol)
Results for BPV viral load and gene expression differed from previous reports and are insufficient to explain the spectrum of tumour phenotypes. Activation of both pro-inflammatory and anti-inflammatory immune pathways in sarcoids could influence tumour growth and effective immune responses, and the contribution of specific infiltrating immune cells requires further investigation.
Journal
|
IL6 (Interleukin 6) • ATR (Ataxia telangiectasia and Rad3-related protein) • IL10 (Interleukin 10) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • TLR9 (Toll Like Receptor 9) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
|
TNFA elevation • TLR9 expression
2ms
The Expression of Toll-like Receptors in Cartilage Endplate Cells: A Role of Toll-like Receptor 2 in Pro-Inflammatory and Pro-Catabolic Gene Expression. (PubMed, Cells)
The expression of TLR1-10 in CEPCs suggests that the CEP is susceptible to PAMP and DAMP stimulation. Enhanced TLR2 expression in MC1, and generally in CEPCs under inflammatory conditions, has pro-inflammatory and pro-catabolic effects, suggesting a potential role in disc degeneration and MC.
Journal • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • TLR9 (Toll Like Receptor 9) • TLR8 (Toll Like Receptor 8) • IL1B (Interleukin 1, beta) • MMP1 (Matrix metallopeptidase 1) • TLR2 (Toll Like Receptor 2)
|
TLR9 expression
7ms
Zhilong Huoxue Tongyu Capsule regulates the macrophage polarization and inflammatory response via the let-7i/TLR9/MyD88 signaling pathway. (PubMed, J Ethnopharmacol)
ZL targeted let-7i to inhibit TLR9 expression, thereby inhibiting the activation of the TLR9/MyD88 pathway, promoting the M2 polarization, and inhibiting the development of inflammation in AIS.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1)
|
TLR9 expression
8ms
Epstein-Barr virus suppresses N6-Methyladenosine modification of TLR9 to promote immune evasion. (PubMed, J Biol Chem)
In clinical lymphoma samples, the expression of METTL3, YTHDF1 and TLR9 was highly correlated with immune cells infiltration. This study reveals a novel mechanism that EBV represses the important innate immunity molecule TLR9 through modulating the host m6A modification system.
Journal • IO biomarker
|
TLR9 (Toll Like Receptor 9) • METTL3 (Methyltransferase Like 3) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1)
|
TLR9 expression
8ms
Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer (clinicaltrials.gov)
P2, N=10, Recruiting, University of Arizona | Trial primary completion date: Mar 2024 --> Mar 2025
Trial primary completion date
|
TLR9 (Toll Like Receptor 9) • CDX2 (Caudal Type Homeobox 2) • MIR30B (MicroRNA 30b)
|
TLR9 expression
9ms
TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth. (PubMed, Antibodies (Basel))
To conclude, our results demonstrate the TLR2 and TLR9-specific intrabody-mediated signaling pathway inhibition of autoregulatory inflammation inside cancer cells and their proliferation, resulting in the suppression of pancreatic tumor cell growth. These findings underscore the potential of specific intrabody-mediated TLR inhibition in the ER relevant for tumor growth inhibition and open up a new therapeutic intervention strategy for the treatment of pancreatic cancer.
Journal • IO biomarker
|
TLR9 (Toll Like Receptor 9) • TLR2 (Toll Like Receptor 2)
|
TLR9 expression
9ms
TLR9 Knockdown Alleviates Sepsis via Disruption of MyD88/NF-κB Pathway Activation. (PubMed, Crit Rev Immunol)
A septic mouse model was established by cecal ligation and puncture (CLP), then administered with lentivirus encoding si-TLR9/LY294002...TLR9 expression was augmented in the cecal tissues, TLR9 and MyD88 interaction was enhanced, nuclear p65 protein level was increased, cytoplasmic p65 protein level was decreased, and the nuclear factor kappa B (NF-κB) pathway was activated in CLP-induced septic mice, while TLR9 knockout protected against CLP-induced sepsis via the MyD88/NF-κB pathway inactivation. Briefly, TLR9 inhibition-mediated protection against CLP-induced sepsis was associated with a reduction in pro-inflammatory cytokine release and a promotion of bacterial clearance via a mechanism involving the MyD88/NF-κB pathway inactivation.
Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TLR9 (Toll Like Receptor 9) • RELA (RELA Proto-Oncogene)
|
TLR9 expression • RELA expression
|
LY294002
10ms
Emerging nanoparticle platforms for CpG oligonucleotide delivery. (PubMed, Biomater Sci)
Moreover, future challenges in the establishment of CpG delivery systems for immunotherapeutic applications are discussed. We expect that the continuously growing interest in the development of CpG-based immunotherapy will certainly fuel the excitement and stimulation in medicine research.
Review • Journal
|
TLR9 (Toll Like Receptor 9)
|
TLR9 expression
10ms
Vaccination against neoantigens induced in cross-priming cDC1 in vivo. (PubMed, Cancer Immunol Immunother)
To obviate the need for a second drug formulation and reduce the risk of toxicity, we exploited the multivalent nature of this targeting platform to co-deliver the TAP siRNA and a DC maturation agent, a CpG containing oligonucleotide, to cDC1 in vivo and show that it was more effective than Clec9a targeting of TAP siRNA in combination with CD40 antibody. This study describes a way to manipulate the function of cDC1 cells in vivo using a broadly applicable antibody-based targeting platform to deliver multiple biological agents to specific cells in vivo to potentiate (immune) therapy and to probe the biology of specific cell types in their natural settings.
Preclinical • Journal
|
TLR9 (Toll Like Receptor 9) • CD40 (CD40 Molecule)
|
TLR9 expression
10ms
Epstein-Barr Virus Promotes Inflammatory Cytokine Production in Human Gingival Fibroblasts. (PubMed, Int Dent J)
Our findings demonstrate that EBV promotes the production of inflammatory cytokines IL-1β and TNF-α and chemokines IL-8 and MCP-1 in HGFs through the TLR9/MyD88/NF-κB pathway.
Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL2 (Chemokine (C-C motif) ligand 2) • IL1B (Interleukin 1, beta)
|
TLR9 expression • CXCL8 expression
10ms
Effect of acupuncture pretreatment on inflammatory response of exercise-induced skeletal muscle damage in rats based on TLR9/MyD88/NF-κB signaling pathway. (PubMed, Zhongguo Zhen Jiu)
Acupuncture pretreatment can alleviate exercise-induced skeletal muscle damage, which may be related to modulating the expression of TLR9/MyD88/NF-κB signaling pathway to inhibit the inflammatory response.
Preclinical • Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
TLR9 expression
11ms
TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma. (PubMed, Am J Physiol Cell Physiol)
Additionally, in vivo experiments further verified that TLR9 promoted tumour growth and immune escape by inhibiting PARP1. Collectively, TLR9 activation induced immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in OSCC, providing important insights for subsequent in-depth exploration of the mechanism of OSCC.
Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TLR9 (Toll Like Receptor 9)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • TLR9 expression
11ms
Intracellular Toll-Like Receptors Modulate Adaptive Immune Responses in Head and Neck Cancer. (PubMed, Viral Immunol)
In conclusion, the role of HPV in OC and OPC is minor, and p16 constitutes a poor biomarker for HPV positivity in Kerala, India. Intracellular TLRs are correlated with the degree of inflammation in OPC but not in OC and may potentially constitute a medical target in the therapy of HNC in the future.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • TLR9 (Toll Like Receptor 9) • TLR8 (Toll Like Receptor 8) • TLR3 (Toll Like Receptor 3) • TLR7 (Toll Like Receptor 7)
|
TLR9 expression • TLR8 expression
12ms
Cervicovaginal microbiota disorder combined with the change of cytosine phosphate guanine motif- toll like receptor 9 axis was associated with cervical cancerization. (PubMed, J Cancer Res Clin Oncol)
Cervicovaginal microbiota dysbiosis might lead to the CpG motif increased, which was closely associated with TLR9 high expression, and ultimately might promote the progression of cervical lesions.
Journal • IO biomarker
|
TLR9 (Toll Like Receptor 9)
|
TLR9 expression
1year
TFAM Modulates Cardiomyocytes Pyroptosis Induced by Ionizing Radiation through mtDNA/TLR9/NF-kB Pathway. (PubMed, Int J Radiat Oncol Biol Phys)
Our study indicated that TFAM regulate irradiated cardiomyocytes pyroptosis through mtDNA/TLR9/NF-kB pathway. We provide a novel mechanism of RIMD, revealing an underappreciated intervention target for RIMD.
Journal
|
IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • TFAM (Transcription Factor A, Mitochondrial)
|
TLR9 expression • NFKB1 expression
1year
Associations Between Serum Soluble Toll-like Receptors 4 and 9 and Breast Cancer in Egyptian Patients. (PubMed, Cancer Control)
Soluble toll-like receptors 4 and sTLR9 are over-expressed in patients with metastatic and non-metastatic BC than in benign cases. The expression levels of sTLR4 and TLR9 have clinical interest as indicators of tumor aggressiveness suggested to be prognostic biomarkers. Toll-like receptors may represent therapeutic targets in breast cancer.
Journal • IO biomarker
|
TLR9 (Toll Like Receptor 9)
|
TLR9 expression
1year
Identification of TLRs as potential prognostic biomarkers for lung adenocarcinoma. (PubMed, Medicine (Baltimore))
Our results provided information on TLRs expression and potential regulatory networks in LUAD. Moreover, our results suggested TLR2/7/8 as a potential prognostic biomarker for lung adenocarcinoma.
Journal • IO biomarker
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • TLR9 (Toll Like Receptor 9) • TLR4 (Toll Like Receptor 4) • TLR8 (Toll Like Receptor 8) • TLR7 (Toll Like Receptor 7) • TLR2 (Toll Like Receptor 2)
|
TLR9 expression
over1year
Neutrophil extracellular traps mediate TLR9/Merlin axis to resist ferroptosis and promote triple negative breast cancer progression. (PubMed, Apoptosis)
Mechanistically, we revealed that NETs could interact with TLR9 to decrease Merlin phosphorylation which contributed to TNBC cell ferroptosis resistance. Our work provides a novel insight into the mechanism of NETs promoting TNBC progression and blocking the key modulator of NETs might be a promising therapeutic strategy in TNBC.
Journal
|
TLR9 (Toll Like Receptor 9)
|
TLR9 expression
over1year
Transcriptional correlation analysis of the CD180/MD-1 complex and toll-like receptors and signaling lymphocyte activation family receptors in chronic lymphocytic leukemia. (IWCLL 2023)
Co-expression analysis of CD180/MD-1 at the transcriptional level has revealed potential novel signaling partners for this TLR complex, providing rationale for further phenotypic and functional studies in CLL. Since CD180 can rewire IgM-mediated signaling to a pro-apoptotic pathway in CLL [8], it will be important to determine if CD180/MD-1 has synergistic or antagonistic effects on the signaling partners proposed here. The high correlation between CD180/MD-1 and TLR10 and SLAMF6 mRNA suggest these receptors as rational starting points for such studies.
IO biomarker
|
CD19 (CD19 Molecule) • TLR9 (Toll Like Receptor 9) • TLR4 (Toll Like Receptor 4) • TLR8 (Toll Like Receptor 8) • SLAMF6 (SLAM Family Member 6) • TLR3 (Toll Like Receptor 3) • CD2 (CD2 Molecule) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex) • CD48 (CD48 Molecule) • TLR7 (Toll Like Receptor 7) • TLR2 (Toll Like Receptor 2)
|
TLR9 expression
over1year
Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification. (IWCLL 2023)
In the presence of the BTK-inhibitor ibrutinib, we found a subset of previously non-responsive NR/RR samples became ‘sensitised’ to TLR9 activation, showing an increase in CLL cell migration in response to stimulation with ODN 2006... In a cohort of 74 primary CLL samples, a dichotomous migratory response was observed in response to the TLR9 agonist ODN 2006. 53% showed an increase in CLL cell migration (categorised as ‘Responders’[R]), whilst 47% showed either no change or a decrease (categorised as ‘Non/ Reverse Responders’[NR/RR]). There was a significant (but not exclusive), correlation with mutational status, with 71 vs.
IO biomarker
|
MCL1 (Myeloid cell leukemia 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD69 (CD69 Molecule) • CD5 (CD5 Molecule) • TLR9 (Toll Like Receptor 9) • ITGA4 (Integrin, alpha 4) • NFKBIA (NFKB Inhibitor Alpha 2) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1)
|
TLR9 expression
|
Imbruvica (ibrutinib)
over1year
Accumulation of plasmacytoid dendritic cell is associated with a treatment response to DNA-damaging treatment and favorable prognosis in lung adenocarcinoma. (PubMed, Front Immunol)
There is an increased pDC in the TME of smokers' lung cancer, and the response of pDC to DNA damaging treatment would lead a conducive environment to ICIs containing regimens. These findings suggest that R&D that induces an increase in the activated pDC population is continuously required to enhance therapeutic effectiveness of ICIs-containing therapies in lung cancer.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • CD163 (CD163 Molecule) • TLR9 (Toll Like Receptor 9)
|
TLR9 expression
over1year
Forecasting most deleterious nsSNPs in human TLR9 gene and their cumulative impact on biophysical features of the protein using in silico approaches. (PubMed, Syst Biol Reprod Med)
In support of our computational findings, the validation of key results using polymerase chain reaction and other experimental methods is warranted in the Indian population. In general, this study might be able to delineate the guideline for identifying the most damaging SNPs and enhances the understating of the risk factors for cancer and disease susceptibilities.
Journal • IO biomarker
|
TLR9 (Toll Like Receptor 9)
|
TLR9 expression
over1year
A TOLL-LIKE RECEPTOR 9 (TLR9) SINGLE NUCLEOTIDE POLYMORPHISM MAY INCREASE COMPLICATIONS TO HELICOBACTER PYLORI INFECTION (DDW 2023)
CONCLUSIONS : Subjects carrying the C/C genotype are more likely to develop complications from H. pylori infection due to greater activation of TLR9-IFNα signaling. The “C” allele is more prevalent in AAm than in Caucasians, suggesting a higher risk in this racial minority.
IO biomarker
|
TLR9 (Toll Like Receptor 9) • CSF2 (Colony stimulating factor 2) • IFNA1 (Interferon Alpha 1) • IL4 (Interleukin 4)
|
TLR9 expression
over1year
Plasmacytoid dendritic cells, prevalent in the TME of smokers, is associated with a good prognosis and treatment response of LUAD. (AACR 2023)
A significant increase in TLR9 expression was observed in or around lung cancer immediately after ionizing radiation or cisplatin treatment in LSL-Kras G12D mouse model... pDC is an innate immune cell population that showed a prominent increase in smokers’ TME compared to that of non-smokers, suggesting that its increase may be one the factors that smokers’ lung cancer show favorable responses to ICI than that of non-smokers. These findings suggest that the pDC signature can be developed as a biomarker predicting the response to ICIs and increasing the number of pDCs or its activity may improve treatment outcome of ICIs.
Tumor mutational burden • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • CD163 (CD163 Molecule) • TLR9 (Toll Like Receptor 9) • IRF4 (Interferon regulatory factor 4) • CDK1 (Cyclin-dependent kinase 1)
|
KRAS G12D • KRAS G12 • TLR9 expression
|
cisplatin
over1year
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes. (PubMed, Int J Mol Sci)
We conclude that MDS HSPCs are primed for inflammasome activation via ox-mtDNA released by pyroptotic cells. Blocking the TLR9/ox-mtDNA axis may prove to be a novel therapeutic strategy for MDS.
Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TLR9 (Toll Like Receptor 9) • NLRP3 (NLR Family Pyrin Domain Containing 3) • IRF7 (Interferon Regulatory Factor 7)
|
TLR9 expression
almost2years
BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists. (PubMed, J Transl Med)
TLR9 is not only a prognostic biomarker but also a potential target for B-ALL therapy. CpG 685 monotherapy might be applicable to Ph B-ALL patients with C-MYC overexpression and without BAX deletion. CpG 685 may also serve as an effective combinational therapy against Ph B-ALL.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BAX (BCL2-associated X protein)
|
MYC overexpression • MYC expression • TLR9 expression • TP53 expression • BAX expression
|
imatinib
almost2years
Effect of Royal Jelly on Gene Expression of Toll-like Receptors 1-9 in Patients with Hepatitis B. (PubMed, Clin Lab)
It seems that royal jelly has anti-viral and anti-inflammatory roles in the in vivo conditions in a dependent manner in TLR3, TLR2, and TLR8. Therefore, it can be suggested as a safe complementary agent for patients with hepatitis B.
Journal • IO biomarker
|
TLR9 (Toll Like Receptor 9) • TLR8 (Toll Like Receptor 8) • TLR3 (Toll Like Receptor 3) • TLR5 (Toll Like Receptor 5) • TLR2 (Toll Like Receptor 2)
|
TLR9 expression
almost2years
TLR9 Exerts an Oncogenic Role in Promoting Osteosarcoma Progression Depending on the Regulation of NF-κB Signaling Pathway. (PubMed, Biol Pharm Bull)
Moreover, the nuclear factor kappa B (NF-κB) signaling pathway was activated by TLR9, and TLR9-induced malignant phenotype of OS cells was abrogated by the NF-κB antagonist BAY11-7082. Our study indicated that TLR9 might play a critical role in facilitating OS progression by activating the NF-κB signaling pathway, which may provide a valuable therapeutic target for OS.
Journal • IO biomarker
|
CCND1 (Cyclin D1) • MMP2 (Matrix metallopeptidase 2) • TLR9 (Toll Like Receptor 9) • CDK2 (Cyclin-dependent kinase 2) • MMP9 (Matrix metallopeptidase 9)
|
CCND1 expression • TLR9 expression • CDK2 expression
|
Bay11-7082
almost2years
TLR9-Selective Therapeutic Targeting of MDS Clones with a CpG Payload-Delivery Strategy (ASH 2022)
Localized targeting was confirmed in vivo by labeling CpG-Den with IR800 revealing specific accumulation in the mice BM. Our data supports TLR9-targeting potential in a proof-of-concept strategy to selectively target primary MDS malignant cells to restore and enhance hematopoiesis while avoiding toxicities.
Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • S100A9 (S100 Calcium Binding Protein A9) • TLR9 (Toll Like Receptor 9)
|
TLR9 expression • S100A9 expression
almost2years
Common Microbial Genital Infections and Their Impact on the Innate Immune Response to HPV in Cervical Cells. (PubMed, Pathogens)
TLR9-increased expression was associated with HPV persistence in previous studies; hence, bacterial coinfections may enhance this risk. Prospective measurements of type III IFNs and IFNLR1 are warranted to evaluate whether this response may act as a double-edged sword in infected epithelia.
Journal • IO biomarker
|
CCL20 (C-C Motif Chemokine Ligand 20) • TLR9 (Toll Like Receptor 9) • TLR7 (Toll Like Receptor 7) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2)
|
TLR9 expression
2years
Toll-like receptors 3, 7, 8 and 9 in Gastric Cancer. (PubMed, APMIS)
Cytoplasmic TLR3, TLR7, TLR8 and TLR9 were not associated with 5-year survival. In conclusion, high nuclear TLR3 expression seems to have prognostic impact in gastric cancer, while TLR7, TLR8 and TLR9 do not.
Journal • IO biomarker
|
TLR9 (Toll Like Receptor 9) • TLR8 (Toll Like Receptor 8) • TLR3 (Toll Like Receptor 3) • TLR7 (Toll Like Receptor 7)
|
TLR9 expression
2years
Human papillomavirus protein E6 regulates Toll like receptor-9 expression in breast cancer cells (SABCS 2022)
These results indicate that HPV may affect breast cancer TLR9 expression and thereby breast cancer prognosis, through treatment responses. Although HPV was not detected in the small pilot set of our clinical samples, this issue needs to be further studied in larger data sets.
IO biomarker
|
ER (Estrogen receptor) • TLR9 (Toll Like Receptor 9)
|
TLR9 expression • ER expression
2years
Extracellular vesicles of Clonorchis sinensis promote IL-6 and TNF-α secretion via the Toll-like receptor 9-mediated ERK pathway in biliary epithelial cells. (PubMed, Dev Comp Immunol)
The ERK inhibitor decreased the CsEVs-induced IL-6 and TNF-α secretion. The present study elucidated for the first time that CsEVs induced IL-6 and TNF-α production in BECs via the TLR9-mediated ERK pathway.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TLR9 (Toll Like Receptor 9) • RELA (RELA Proto-Oncogene)
|
TLR9 expression • IL6 expression
2years
Association between Tissue Expression of Toll-Like Receptor and Some Clinicopathological Indices in Oral Squamous Cell Carcinoma. (PubMed, Rep Biochem Mol Biol)
The follow-up time to recurrence in advanced stage was statistically lower than early stage (p= 0.007). Overexpression of TLRs 2, 9 play role in the pathogenesis and tumor development of OSCC and can be applied as biomarker in prognostic approaches.
Journal • IO biomarker
|
TLR9 (Toll Like Receptor 9) • TLR2 (Toll Like Receptor 2)
|
TLR9 expression
2years
Toll-like receptor 9 promotes initiation of gastric tumorigenesis by augmenting inflammation and cellular proliferation. (PubMed, Cell Mol Gastroenterol Hepatol)
Our data reveal that TLR9 promotes the initiating stages of GC and facilitates Helicobacter-induced gastric inflammation and hyperplasia, thus providing in vivo evidence for TLR9 as a candidate therapeutic target in GC.
Journal • IO biomarker
|
TLR9 (Toll Like Receptor 9)
|
TLR9 expression